Floatz logo

Inotuzumab Ozogamicin

Burkitt-Like Lymphoma With 11q Aberration

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Burkitt-Like Lymphoma With 11q Aberration cohort.

Asset / SponsorPhaseRating
METHOTREXATE
M.D. Anderson Cancer Center
Phase 1/2CCC
Blinatumomab
M.D. Anderson Cancer Center
Phase 1/2CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 1/2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 1/2CCC
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 9 →

Same molecule, other indications

Inotuzumab Ozogamicin is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B Lymphoblastic LymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →